Literature DB >> 11013683

Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment.

E Bouffet1, A Jouvet, P Thiesse, M Sindou.   

Abstract

This series reports a pilot study of chemotherapy conducted for newly diagnosed and relapsing patients with oligodendrogliomas and oligoastrocytomas. Twenty-three patients with clinically or histologically aggressive tumours were eligible to receive procarbazine CCNU and vincristine (PCV) chemotherapy followed by radiotherapy in previously non irradiated patients. Sixteen (69%) responded to chemotherapy with complete responses in two patients and partial responses in 14. Previously irradiated patients were as likely to respond to PCV as those previously non irradiated. An over 1-year history of seizures was the main clinical prognostic factor of response. All toxicities were manageable and no treatment related deaths occurred. Chemotherapy is an effective treatment in aggressive oligodendrogliomas. Further studies must assess the role of chemotherapy in the multidisciplinary management of oligodendroglioma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11013683     DOI: 10.1080/02688699845023

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  7 in total

1.  Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.

Authors:  Tosol Yu; Hyun-Cheol Kang; Do Hoon Lim; Il Han Kim; Woong-Ki Chung; Chang-Ok Suh; Byung Ock Choi; Kwan Ho Cho; Jae Ho Cho; Jin Hee Kim; Chul-Kee Park; Yong-Kil Hong; In Ah Kim
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

2.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

3.  Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.

Authors:  Gokhan Ozyigit; Cem Onal; Murat Gurkaynak; Figen Soylemezoglu; Faruk Zorlu
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

4.  ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment.

Authors:  Yangtao Xu; Xiaoqin He; Junjian Deng; Lin Xiong; Biao Chen; Jiayu Chen; Xiaoyu Zhang; Wenliang Chen; Xin Liu; Xinyao Hu; Jiayi Li; Shan Jiang; Yang Shen; Ximing Xu
Journal:  Oxid Med Cell Longev       Date:  2022-05-09       Impact factor: 7.310

5.  Posterior fossa oligodendroglioma.

Authors:  Naveen Chitkara; Rakesh Chanda; Anil K Thakur; Seema Chanda; N K Sharma
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

6.  Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children.

Authors:  Enrique López-Aguilar; Ana Carolina Sepúlveda-Vildósola; Hugo Rivera-Márquez; Fernando Cerecedo-Díaz; Martha Valdés-Sánchez; Sandra Delgado-Huerta; Volkmar Wanzke-del Angel; Guillermo Ramón-García; Héctor Rodríguez-Jiménez; Isidro Hernández-Contreras; Enrique Santacruz-Castillo; Hugo A Romo-Rubio
Journal:  Childs Nerv Syst       Date:  2003-11-12       Impact factor: 1.475

Review 7.  Oligodendroglioma.

Authors:  Thomas L Ellis; Volker W Stieber; Rebekah C Austin
Journal:  Curr Treat Options Oncol       Date:  2003-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.